Skip to content
Winfred
Sign up
Back to Startups
T-Therapeutics

T-Therapeutics

Follow

Developer of next-generation T cell receptor therapeutics for oncology and immunology.

United Kingdom— Founded 2022— Website
£72.3MTotal raised

T-Therapeutics develops next-generation T cell receptor therapeutics to treat cancer and autoimmune diseases. The biotechnology company spun out of the University of Cambridge to advance its proprietary drug development programmes.

Categories

BioTechAI/MLBig Data

Founders

Allan Bradley

Allan Bradley

Chief Scientific Officer

Allan serves as chief scientific officer at T-Therapeutics and co-founded ExpressionEdits, following earlier roles as chief executive at T-Therapeutics and director at Kymab and PetMedix.

LinkedIn

Investors

  1. Series A
    £24.3M
    BGF
    BGF
    Tencent
    Tencent
    Sofinnova Partners
    Sofinnova Partners    Follow-on
    FC
    F-Prime Capital    Follow-on
    DV
    Digitalis Ventures    Follow-on
    Cambridge Innovation Capital
    Cambridge Innovation Capital    Follow-on
    SV
    Sanofi Ventures    Follow-on
    Uo
    University of Cambridge    Follow-on
  2. Series A
    £48.0M
    Sofinnova Partners
    Sofinnova Partners    Lead
    FC
    F-Prime Capital    Lead
    DV
    Digitalis Ventures    Lead
    Cambridge Innovation Capital
    Cambridge Innovation Capital    Lead
    SV
    Sanofi Ventures
    Uo
    University of Cambridge

Funding history